Is Immunocore Holdings Ltd (IMCR) overvalued? · rev $310.2M
Immunocore Holdings Ltd (IMCR) is a biotechnology company listed on NASDAQ.
This page asks whether Immunocore Holdings Ltd (IMCR) looks expensive on cached numbers — not a short thesis.
Latest reported IMCR revenue for 2024-12-31 was $310.2M. Net income was -$51.1M. Revenue was up 24.4% from 2023-12-31 to 2024-12-31. IMCR currently screens at market cap $1.45B.
IMCR currently screens at market cap $1.45B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IMCR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IMCR stock page for the full model, not this heading.
Not investment advice.